ONO L 0.03mg/kg/min 1min 0.01mg/kg/min 10min M 0.03mg/kg/min 1min 0.02mg/kg/min 10min H 0.06mg/kg/min 1min 0.04mg/kg/min 10min 3 1) LSD p=0.000

Size: px
Start display at page:

Download "ONO L 0.03mg/kg/min 1min 0.01mg/kg/min 10min M 0.03mg/kg/min 1min 0.02mg/kg/min 10min H 0.06mg/kg/min 1min 0.04mg/kg/min 10min 3 1) LSD p=0.000"

Transcription

1 ONO L 0.03mg/kg/min1min0.01mg/kg/min10minM 0.03mg/kg/min1min0.02mg/kg/min 10minH 0.06mg/kg/min1min0.04mg/kg/min10min 3 1) LSD p=0.0001) 30 2) FACCFSVcfc LVESWS EDA DT MH LSD p<0.05)peak E peak A E/A 3) LMH RR LSD L p=0.0021mh p=0.0001)pq QRS QT ST 4) ONO-1101 ONO-1101 ONO-1101 ONO

2 100 / Hypovolemia 4 160/95 mmhgwho ONO ) 20 ONO mg/ mg/kg/min 0.01mg/kg/min mg/ kg/min 0.02mg/kg/min 0.06mg/kg/min 0.04mg/kg/min

3 1 50mg 5mL 1 ml/min mg 5mL 10 ml/min nifedipinenicardipinenilvadipine Ca FAC( )CFS( )Vcfc( )EDA( )LVESWS( )peak E( E )peak A( A )E/A( E / A ) DT(E ) 502

4 % 2 20% 3 20% 4 10% % 3 (20% 4 10% 5 10%

5 (RR PQ QRS QT ST ) (FAC, CFS, Vcfc) (LVESWS) (peak E, peak A, ) (LSD) 5% 1) T.Ryan, A.Timoney, A.J.Cunningham : Use of transoesophageal echocardiography to manage beta-adrenoceptor block and assess left ventricular function In a patient with pheaeochromocytoma. Br.J.Anaeth. 70: , ) Christopher J.O., David M.R., Jeffrer S.S. et al. : The effect of esmolol pretreatment on the incidence of regional wall motion abnomrmalities during electroconvulsive therapy. Anaeth.Analg. 82: ,

6 0.03mg/kg/min mg/kg/min L )0.06mg/kg/min mg/kg/min M )0.125mg/kg/min mg/kg/min H ) %90.7% ONO-1101 L M H /95mmHg / 4 85 / 505

7 506

8 LSD p=0.0001)h 30 LSD 30 p= p=0.0012) ANOVA : p= E1 507

9 85.7% 508

10 (mmhg) ANOVA : N.S. (FAC) (CFS) (Vcfc) (EDA) (LVESWS) peak E (peak E)peak A (peak A)peak E /peak A (E/A) E (DT) M H LSD p<0.05) DT 30 FAC (%) CFS (%) Vcfc (circ/sec) (ANOVA) 509

11 EDA (cm 2 ) LVESWS (g/cm 2 ) (ANOVA) peak E (cm/sec) peak A (cm/sec) E/A DT (cm/sec) (ANOVA) RR LSD L p=0.0021mh p=0.0001)pq QRS QT ST 510

12 ONO-1101 DT 1 DT 30 ONO ) Mantero A, Gentile F, Gualtierotti C, et al. : Left ventricular diastolic parameters in 288 normal subjects from 20 to 80 years old. Eur Heart J 16:94-105,

13 ONO %(17/28) ) mg/kg/min ONO-1101 ONO mg/kg/min mg/kg/min 10 ONO ASAAmerican Society of Anesthesiologist

14 ONO ONO mg/ 0.125mg/kg/min1 0.04mg/kg/min mg/kg/min 1 50mg 5mL 1 ml/min mg 5mL 10 ml/min nifedipinenicardipinenilvadipine Ca

15 / / 115 / / 130 / /

16 (RR PQ QRS QT ST ) t 5% mg/kg/min mg/kg/min 10 L ) 0.06mg/kg/min mg/kg/min 10 M ) 0.125mg/kg/min mg/kg/min 10 H )3 3 H 0.04mg/kg/min mg/kg/min 515

17 30 ECG

18 / 60.7% 517

19 / / / / 31.0%(9/29) 518

20 / GPT 519

21 72.4% 520

22 53.6% mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg RPP bpmmmHg bpmmmHg bpmmmHg bpmmmHg 521

23 ONO-1101 ONO ng/mL ng/mL 0.04mg/kg/min 1000ng/mL ng/mL pg/mL pg/mL pg/mL pg/mL paired t p= p= p=0.0001) pg/mL pg/mL pg/mL paired t p= p=0.0213) pg/mL / / 50 / /) / mmhg mmHg

24 ONO % ONO % 523

25 RR QT paired t p=0.0001)qrs QTc PQ 524

26 ONO /51mmHg /74mmHg 8 76/53mmHg 9 60 /

27 526

28 1 ONO / 60.7% 1 RPP bpm mmhg bpmmmHg ONO

1 1)

1 1) --------------------------------------------------------- 1 -------------------------------------------------------------------------- 1 -------------------------------------------------------------------------------------

More information

福島県2012-初校.indd

福島県2012-初校.indd 2012 FUKUSHIMA http://www.kairyudo.co.jp/ 2 4 5 1 2 3 2 3 20092008 kg cm 1500m 1000m 20m 50 m cm m 12 25.08 6.15 24.66 6.17 22.03 4.23 22.08 4.45 13 30.32 6.40 30.10 6.99 24.37 4.17 23.97 4.48 14 35.10

More information

2 2000 3 31 209 5.6.2 2000 3 31 209211 52

2 2000 3 31 209 5.6.2 2000 3 31 209211 52 10 45m 700900mm 400600mm 1m 3060 12m 11.5cm 40cm 900mm 2000 5 71 2.4-1 2000 3 31 237245 2000 5 7172 51 2 2000 3 31 209 5.6.2 2000 3 31 209211 52 6 1 1 900mm 1 2 3 53 2000 3 31 234 5.6.34 2000 3 31 232234

More information

「諸雑公文書」整理の中間報告

「諸雑公文書」整理の中間報告 30 10 3 from to 10 from to ( ) ( ) 20 20 20 20 20 35 8 39 11 41 10 41 9 41 7 43 13 41 11 42 7 42 11 41 7 42 10 4 4 8 4 30 10 ( ) ( ) 17 23 5 11 5 8 8 11 11 13 14 15 16 17 121 767 1,225 2.9 18.7 29.8 3.9

More information

2

2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 10 6 15 7 13 7 14 13 31 13 13 9 30 13 10 14 13 10 25 13 11 29 13 11 30 14 111 14 223 14 2 23 3 17 14 3 17 14 3 21 14 3 26 13 11 29 5 2 2 14 1 11 1 3 28 1 3 14 2 28 1 28

More information

METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,

METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV, 2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002

More information

3 4 6 7 8 9 10 12 14 2 3

3 4 6 7 8 9 10 12 14 2 3 3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15

More information

untitled

untitled g g/cm3 g / cm3 g g g g/cm3 cm2 kv

More information

1 2

1 2 1 2 4 3 5 6 8 7 9 10 12 11 0120-889-376 r 14 13 16 15 0120-0889-24 17 18 19 0120-8740-16 20 22 21 24 23 26 25 28 27 30 29 32 31 34 33 36 35 38 37 40 39 42 41 44 43 46 45 48 47 50 49 52 51 54 53 56 55 58

More information

3 5 6 7 7 8 9 5 7 9 4 5 6 6 7 8 8 8 9 9 3 3 3 3 8 46 4 49 57 43 65 6 7 7 948 97 974 98 99 993 996 998 999 999 4 749 7 77 44 77 55 3 36 5 5 4 48 7 a s d f g h a s d f g h a s d f g h a s d f g h j 83 83

More information

:,, : - 7 -

:,, : - 7 - 31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6

More information

4.4 R............................................. 13 4.5 q.............................................. 13 4.6 s....................................

4.4 R............................................. 13 4.5 q.............................................. 13 4.6 s.................................... 2014.04.12 2014.12.12 1 3 2 4 2.1............................................ 4 2.2 Einthoven triangle........................................ 4 2.3............................................ 4 2.4.............................................

More information

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI 20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old

More information

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

P1-1 P1-2 P1-3 P1-4 P1-5 P1-6 P3-1 P3-2 P3-3 P3-4 P3-5 P3-6 P5-1 P5-2 P5-3 P5-4 P5-5 P5-6 P7-1 P7-2 P7-3 P7-4 P7-5 P7-6 P9-1 P9-2 P9-3 P9-4 P9-5 P9-6 P11-1 P11-2 P11-3 P11-4 P13-1 P13-2 P13-3 P13-4 P13-5

More information

MH MH 9.50 8.50 9.40 8.40 9.30 9.20 8.30 9.10 9.00 8.20 8.90 8.80 8.10 8.70 8.60 8.00 8.50 7.90 8.40 8.30 7.80 8.20 8.10 7.70 8.00 7.60 7.90 7.80 7.50 7.70 7.60 7.40 1 7.50 7.40 7.30 2 7.30 7.20 7.20

More information

Symposium 46 I I II II III III 1 12 54/ narrow QRS tachycardia 139/ P V1 HIS 5 6 HIS 3 4 HIS 1 2 CS 9 10 CS 7 8 CS 5 6 CS 3 4 CS 1 2 RV 3 4 RV 1 2 100

Symposium 46 I I II II III III 1 12 54/ narrow QRS tachycardia 139/ P V1 HIS 5 6 HIS 3 4 HIS 1 2 CS 9 10 CS 7 8 CS 5 6 CS 3 4 CS 1 2 RV 3 4 RV 1 2 100 Symposium 46 Inappropriate Sinus Tachycardia1 inappropriate sinus tachycardiaistp 100/ 1 IST 2 IST IST atrio ventricular nodal reentrant tachycardiavnrt IST 1 26 2011 24 2013 2013 7 54/ 1 narrow QRS 139/aVFP1

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

098青沼班DGfinal修正0506.indd

098青沼班DGfinal修正0506.indd 1 2011 Brugada QT 2005 2006 2007 Brugada Brugada 20 QT 70 2007 Brugada ICD ICD 5 2 QT Brugada 2012 QT QT QT Brugada Brugada 5 AHA/ACC ESC I II III A B C I II IIa IIb III A B C QT long QT syndrome LQTS

More information

mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD

mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD 31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl

More information

, 360ml P , 360ml P , 360ml P , 40, 720ml P , 14, 2

, 360ml P , 360ml P , 360ml P , 40, 720ml P , 14, 2 3-1 3-1 20 2600, 20, 360ml P.35 3-2 3-2 16 2700, 16, 280ml P.35 3-3 3-3 20 2600, 20, 360ml P.35 3-4 3-4 19 2600, 19, 340ml P.35 3-5 3-5 20 2900, 20, 360ml P.35 3-6 3-6 18 3000, 18, 320ml P.35 3-7 3-7 18

More information

ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G

More information

1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR

More information

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b) 2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)

More information

秋田県2012-初校.indd

秋田県2012-初校.indd http://www.kairyudo.co.jp/ 2012 AKITA 2 3 4 10 15 1 2 3 2 cm 110.7 111.6 109.8 110.6 5 kg 19.0 19.5 18.6 19.1 cm 61.9 62.2 61.5 61.6 cm 116.7 117.8 115.8 116.8 6 kg 21.4 22.5 21.0 21.9 cm 64.9 65.4 64.5

More information

0.01mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.05 mg/ ç 0.05 mg/ ç 0.01 mg/ ç 0.01 mg/ ç 0.0005mg/ ç 0.0005mg/ ç 0.02 mg/ ç 0.02 mg/ ç 0.002 mg/ ç 0.002 mg/ ç 0.004 mg/ ç 0.004 mg/ ç 0.02 mg/ ç 0.02 mg/

More information

02.O...r.A..

02.O...r.A.. 8 300ha k (m 3 / / ) (0 2 ) 0405 135 270 2 12 0540 162 351 12 24 0810 216 486 500kg 135 459 127 1987 (m 3 / / ) 0566 2266 5947 9 18kg 0057 0425 1019 18 45 0142 0566 1358 45 675 0198 0708 2038 675 945 0283

More information

2

2 a DEF MNO WXYZ ABC JKL TUV GHI PQRS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 2 3 RUN VB-F050 ALARM a 1 2 4 3 5 6 4 7 5 8 9 10 6 11 12 13 7 14 15 16 18 17 8 9 1 10 1 11 1 12 1 13 1 14 1 15 1 16 VB-F050

More information

ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm

ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm 1 186 186 (1) - 192 (2) (ISAintrinsic sympathomimetic activity) 199 (3) ( MSAmembrane stabilizing activity) 2 (4) 21 (5) 212 (6) 216 (7) 219 (8) 224 (9) (ASL-8123) - 229 (1) d-esl l-esl - 231 2 235 235

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

岩手県2012-初校.indd

岩手県2012-初校.indd http://www.kairyudo.co.jp/ 2012 IWATE 2 3 4 16 1 2 3 2 14 165.6 165.2 55.2 54.3 88.6 88.1 cm kg cm 13 160.1 159.7 50.1 49.1 85.1 84.9 12 153.5 152.5 46.3 44.2 81.9 81.3 13 155.4 154.9 48.9 47.3 84.2 83.7

More information

(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37

(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37 4. 98 () θ a = 5(cm) θ c = 4(cm) b = (cm) () D 0cm 0 60 D 99 () 0m O O 7 sin 7 = 0.60 cos 7 = 0.799 tan 7 = 0.754 () xkm km R km 00 () θ cos θ = sin θ = () θ sin θ = 4 tan θ = () 0 < x < 90 tan x = 4 sin

More information

:30 100m 4 3 (2 ) 5 (3 ) 7 (1 ) 16 OB OG m 200m (2 ) m (1 ) 4 (3 ) 2m m 10:35 100m 3 (3 ) 5 OB OG (1

:30 100m 4 3 (2 ) 5 (3 ) 7 (1 ) 16 OB OG m 200m (2 ) m (1 ) 4 (3 ) 2m m 10:35 100m 3 (3 ) 5 OB OG (1 2003 10 1 1 1.1............ 1 1.2............ 2 1.3.......... 2 1.4.............. 2 1.5.............. 7 1.6.............. 10 2 11 100m,200m 200m 21 2.1............ 11 2m A 1 2.2.... 11 1500m 3 1 14m15

More information

20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine

More information

青森県2012-初校.indd

青森県2012-初校.indd http://www.kairyudo.co.jp/ 2012 AOMORI 2 3 9 16 1 2 3 2010 6 128.9 128.2 128.7 8 9 31.7 30.0 31.7 30.0 22.5 21.4 21.9 21.0 117.2 116.7 116.3 115.8 65.1 64.9 64.7 64.5 7 25.3 24.0 24.9 23.5 123.1 122.5

More information

2002 (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (8) No 2,500 3 200 200 200 200 200 50 200 No, 3 1 2 00 No 2,500 200 7 2,000 7

More information

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30

More information

... 6

... 6 ... 6 1) 2) No. 01 02 03 04 05 06 07 08 09 10 11 12 No. 1 2 2 3 3cm 4

More information

untitled

untitled 1....1 2....2 2.1...2 2.2...2 3....14 3.1...14 3.2...14 4....15 4.1...15 4.2...18 4.3...21 4.4...23 4.5...26 5....27 5.1...27 5.2...35 5.3...54 5.4...64 5.5...75 6....79 6.1...79 6.2...85 6.3...94 6.4...

More information

113 120cm 1120cm 3 10cm 900 500+240 10 1 2 3 5 4 5 3 8 6 3 8 6 7 6 8 4 4 4 4 23 23 5 5 7

More information

untitled

untitled 21 14 487 2,322 2 7 48 4 15 ( 27) 14 3(1867) 3 () 1 2 3 ( 901923 ) 5 (1536) 3 4 5 6 7 8 ( ) () () 9 10 21 11 12 13 14 16 17 18 20 1 19 20 21 22 23 21 22 24 25 26 27 28 22 5 29 30cm 7.5m 1865 3 1820 5

More information

1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24

1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24 15 4 16 1988 63 28 19314 29 3 15 4 16 19283 15294 16 1930 113132 3 15 4 16 33 13 35 12 3 15 4 16 1945 10 10 10 10 40 1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11

More information

裁定審議会における裁定の概要 (平成23年度)

裁定審議会における裁定の概要 (平成23年度) 23 23 23 4 24 3 10 11 12 13 14 () 1 23 7 21 23 12 14 (19 ) 30 1.876% 60 8 24 19 78 27 1 (10) 37 (3) 2 22 9 21 23 5 9 21 12 1 22 2 27 89 10 11 6 A B 3 21 12 1 12 10 10 12 5 1 9 1 2 61 ( 21 10 1 11 30 )

More information

Microsoft Word - 入居のしおり.doc

Microsoft Word - 入居のしおり.doc 1 1 2 2 2 3 2 4 3 5 3 6 3 7 3 8 4 1 7 2 7 3 7 4 8 5 9 6 9 7 10 8 10 9 11 10 11 11 11 12 12 13 13 1 14 2 17 3 18 4 19 5 20 6 22 (1) 24 (2) 24 (3) 24 (4) 24 (5) 24 (6) 25 (7) 25 (8) 25 (9) 25 1 29 (1) 29

More information

和県監査H15港湾.PDF

和県監査H15港湾.PDF ...1...1...1...1...1...1...1...1...2...2...2...3...3...3...5...5...10...11...12...13...13...13...14...14...14...14...14...14...15...15...15...15...15 ...16...17 14...17...18...18...19...21...23 2...25...27...27...28...28...28

More information

( )

( ) ( ) () () 3 cm cm cm cm cm cm 1000 1500 50 500 1000 1000 1500 1000 10 50 300 1000 2000 1000 1500 50 10 1000 2000 300 50 1000 2000 1000 1500 50 10 1000 2000 300 30 10 300 1000 2000 1000 1500 1000

More information

-26-

-26- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- cm -39- -40- 1 2 3 4 4 3 2 1 5 5-41- -42- -43- -44- -45- -46- -47- -48- -49- -50- cm -51- -52- -53- -54- -55- -56- -57- -58- -59- -60-

More information

-1- 4 1 2 4-2- -- 2 2 cm 0 80cm 2 80cm 80cm 80cm 50cm 80cm 50cm 6 80cm 100 50 50 cm 10 6 4 50cm 4 4 50cm -4- -5- cm 50cm 4 4 4 50cm 50cm 4 80cm 50cm 80cm 50cm 6 cm -6- 20 250cm 1 2 1 4 0cm 60cm cm cm 1

More information

untitled

untitled () () () () () ( ) () ( ) () ( ) () 2 () () 2 () () ( ) () () () 2 () () 2 3 ( ) () ( ) 2 3 4 () () 2 3 4 () () ( )( ) ( ) 2 ( ) 3 () () 2 3 () () 2 3 () () () () () () () () (( ) ( ) (( ))( )( ) ) 2 3

More information

河川砂防技術基準・基本計画編.PDF

河川砂防技術基準・基本計画編.PDF 4 1 1 1 1 1 2 1 2.1 1 2.2 2 2.3 2 2.4 2 3 2 4 3 2 4 1 4 1.1 4 1.2 4 2 4 2.1 4 2.2 4 2.3 5 2.4 5 2.5 5 2.5.1 5 2.5.2 5 2.6 5 2.6.1 5 2.6.2 5 2.6.3 5 2.6.4 5 2.6.5 6 2.7 6 2.7.1 6 2.7.2 6 2.7.3 6 2.7.4

More information

4 100g

4 100g 100g 10 20 30 40 50 60 70 80 4 5 7 9 12 15 19 24 60 100 10 80 100 20 10 5 20 195 20-1- 60 60 15 100 60 100 15 15 15 100 15 15 60 100 10 60 100 100 15 10 10 60 100 15 10 15 10 5-2- 80 80 24 100 80 100 24

More information

70% ADCA 28% SCA6 30% MJD 30% DRPLA 13% 20% SCA1 4% SCA2 3% RCA 2% 537 25 T2 C3 C6) LCL MRI OB ph3 ph9 60/40/20mg/ 1000mg/ 3 500mg/ 6 1000mg/ 3 6/ 2 1 2 3 50 25 0 75 100 % 100 33 67 75 80

More information

MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2

MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2 2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.

More information

Microsoft Word - 14_LCMS_アクリルアミド

Microsoft Word - 14_LCMS_アクリルアミド 3--2-3-Iodo-2-propynyl butylcarbamate (IPBC) Carbamic acid, butyl-, 3-iodo-2-propynyl ester Iodocarb CAS 55406-53-6 C 8 H 12 NO 2 I C (g/cm 3 ) (mmhg) log P ow 281.09 (280.9910) 64 68 1.51 1.57 (20 C)

More information

I PD-I-3 VA ICD 2006 NYHA ~ LVEF 35% a ICD SCD-HeFT ICD MADIT- ICD a CABG-Patch ICD EF b MADITø MADIT- MUSTT EPS EPS 19 EPS 5/19 VA PD-I-4 Holter LP f

I PD-I-3 VA ICD 2006 NYHA ~ LVEF 35% a ICD SCD-HeFT ICD MADIT- ICD a CABG-Patch ICD EF b MADITø MADIT- MUSTT EPS EPS 19 EPS 5/19 VA PD-I-4 Holter LP f J Arrhythmia Vol 23 (Suppl) 2007 PD-I-1 OACIS 95% 6.4 (1.5 27.8 4.3 (1.0 18.5), 0.2 (0.05 0.93), respectively MADIT LVEF 30% 192 2.0 12.4% 24 3.1% MADIT 12.1% p=.001), ICD direct PCI OACIS (Osaka Acute

More information